+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pulmonary Drug Delivery Systems Market - Forecasts from 2025 to 2030

  • PDF Icon

    Report

  • 140 Pages
  • May 2025
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 6099670
The Pulmonary Drug Delivery Systems Market will reach US$53.269 billion in 2030 from US$43.182 billion in 2025 at a CAGR of 4.29% during the forecast period.

The increasing prevalence of the chronic respiratory disease worldwide will drive the market growth of the pulmonary drug delivery systems market during the forecast period. According to the World Health Organization, more than 1 billion people suffer from either acute or chronic respiratory conditions. Around 4 million people die prematurely from chronic respiratory diseases. In addition, nearly 235 million people suffer from asthma in the world and over 80% of the deaths due to Asthma occur in low and middle-income countries. The increasing incidence of such diseases will support the market growth as more patients will require the pulmonary drug delivery system for their treatment.

The market for pulmonary drug delivery systems is expected to grow due to increasing health awareness and rising investments in the healthcare and drug delivery sectors by both public and private entities. Additionally, initiatives by government bodies worldwide are enhancing public health awareness. For example, the National Asthma Control Program (NACP) by the CDC funds education for asthma patients, encouraging the adoption of pulmonary drug delivery systems for treatment. Such efforts are anticipated to drive market growth throughout the forecast period.

The global pulmonary drug delivery systems market report provides a comprehensive analysis of the industry, offering strategic and executive-level insights supported by data-driven forecasts. This regularly updated report equips decision-makers with actionable intelligence on market trends, emerging opportunities, and competitive dynamics. It evaluates demand for various pulmonary drug delivery technologies, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and soft mist inhalers, while examining applications and end-user segments such as hospitals, home care settings, and specialty clinics. The report also explores technological advancements, key government policies, regulatory frameworks, and macroeconomic factors, delivering a holistic market perspective.

Some of the major players covered in this report include Philips Respironics, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., 3M, PARI GmbH, F. Hoffmann-La Roche AG, Gilbert Technologies, AstraZeneca PLC among others.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

How can the data from this report be utilized?

Industry & Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, and Competitive Intelligence.

Report Coverage

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Pulmonary Drug Delivery Systems Market Segmentation

Pulmonary Drug Delivery Systems Market Segmentation by Product:

The market is analyzed by product into the following:
  • Metered-dose inhalers (MDIs)
  • Dry Powder Inhalers (DPIs)
  • Soft Mist Inhaler (SMI)
  • Nebulizers

Pulmonary Drug Delivery Systems Market Segmentation by Formulation Type:

The report analyzed the market by formulation type as below:
  • Suspension Aerosol
  • Solution Aerosol
  • Dry Powder Formulation

Pulmonary Drug Delivery Systems Market Segmentation by Application:

The market is analyzed by application into the following:
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Cystic Fibrosis
  • Allergic Rhinitis
  • Other Respiratory Conditions

Pulmonary Drug Delivery Systems Market Segmentation by End-User Segment:

The report analyzed the market by end-user segment as below:
  • Hospitals & Clinics
  • Homecare Settings
  • Diagnostic Centers
  • Others

Pulmonary Drug Delivery Systems Market Segmentation by Distribution Channel Segment:

The report analyzed the market by distribution channel segment as below:
  • Offline
  • Online

Pulmonary Drug Delivery Systems Market Segmentation by Regions:

The study also analysed the pulmonary drug delivery systems market into the following regions, with country level forecasts and analysis as below:
  • North America (US, Canada and Mexico)
  • South America (Brazil, Argentina, and Others)
  • Europe (Germany, UK, France, Spain and Others
  • Middle East and Africa (Saudi Arabia, UAE and Others)
  • Asia-Pacific (China, Japan, India, South Korea, Thailand, Indonesia, and Others)

Pulmonary Drug Delivery Systems Market Report Coverage

This report provides extensive coverage as explained in the points below:

  • Market size, forecasts, and trends by different types, with historical revenue data and analysis focusing on key factors driving adoption, current challenges faced by key players, and major growth areas.
  • Market size, forecasts, and trends by product, with historical revenue data and analysis.
  • Market size, forecasts, and trends by formulation type, with historical revenue data and analysis.
  • Market size, forecasts, and trends by application, with historical revenue data and analysis of sales based on applications.
  • Market size, forecasts, and trends by end-user segment, with historical revenue data and analysis across various segments.
  • Market size, forecasts, and trends by distribution channel segment, with historical revenue data and analysis across various segments
  • Pulmonary drug delivery systems market is also analysed across different regions, with historical data, regional share, attractiveness and opportunity of these solutions in different countries. The growth prospects and key players operating in these markets. The section also dwells on the macro factors, economic scenario and other complementing factors aiding in market growth.
  • Market dynamics: The section details the market growth factors, restraints, and opportunities in the market. The segment also presents complete market scenario with the help of Porter's five forces model.
  • Competitive Intelligence: A thorough investigation on the competitive structure of the market presented through proprietary vendor matrix model, market share analysis of key players, insights on strategies of key players and recent major developments undertaken by the companies to gain competitive edge.
  • Research methodology: The assumptions and sources which were considered to arrive at the final market estimates. Additionally, how our model is refined to ensure most significant factors are taken into consideration with the proper hypothesis and bottom-up and top-down approaches enhance the reliability of forecasts further strengthening the trustworthiness of the numbers being presented.

Reasons to Purchase This Report

  • The report provides a strategic outlook of the pulmonary drug delivery systems market to decision-makers, analysts and other stakeholders in easy-to-read format for taking informed decisions.
  • The charts, tables and figures make it easy for executives to gain valuable insights while skimming through the report.
  • Analyst support through calls and email for timely clarification and incorporating additional requests.
  • Option of presentation or doc format with the estimates file to take care of diverse requirements.
  • 15% free customization to help cater for additional requirements with significant cost-savings.

Table of Contents

1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY PRODUCT
5.1. Introduction
5.2. Metered-dose inhalers (MDIs)
5.3. Dry Powder Inhalers (DPIs)
5.4. Soft mist inhaler (SMI)
5.5. Nebulizers
6. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY FORMULATION TYPE
6.1. Introduction
6.2. Suspension Aerosol
6.3. Solution Aerosol
6.4. Dry Powder Formulation
7. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY APPLICATION
7.1. Introduction
7.2. Asthma
7.3. Chronic Obstructive Pulmonary Disease (COPD)
7.4. Cystic Fibrosis
7.5. Allergic Rhinitis
7.6. Other Respiratory Conditions
8. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY END-USER INDUSTRY
8.1. Introduction
8.2. Hospitals & Clinics
8.3. Homecare Settings
8.4. Diagnostic Centers
8.5. Others
9. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY DISTRIBUTION CHANNEL INDUSTRY
9.1. Introduction
9.2. Offline
9.3. Online
10. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. USA
10.2.2. Canada
10.2.3. Mexico
10.3. South America
10.3.1. Brazil
10.3.2. Argentina
10.3.3. Others
10.4. Europe
10.4.1. United Kingdom
10.4.2. Germany
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Others
10.5. Middle East and Africa
10.5.1. Saudi Arabia
10.5.2. UAE
10.5.3. Others
10.6. Asia Pacific
10.6.1. China
10.6.2. Japan
10.6.3. India
10.6.4. South Korea
10.6.5. Taiwan
10.6.6. Thailand
10.6.7. Indosneisa
10.6.8. Others
11. COMPETITIVE ENVIRONMENT AND ANALYSIS
11.1. Major Players and Strategy Analysis
11.2. Market Share Analysis
11.3. Mergers, Acquisitions, Agreements, and Collaborations
11.4. Competitive Dashboard
12. COMPANY PROFILES
12.1. Philips Respironics
12.2. GlaxoSmithKline PLC
12.3. Boehringer Ingelheim GmbH
12.4. Teva Pharmaceutical Industries Ltd.
12.5. AptarGroup, Inc.
12.6. PARI GmbH
12.7. F. Hoffmann-La Roche AG
12.8. Gilbert Technologies
12.9. AstraZeneca PLC
13. APPENDIX
13.1. Currency
13.2. Assumptions
13.3. Base and Forecast Years Timeline
13.4. Key Benefits for the Stakeholders
13.5. Research Methodology
13.6. Abbreviations

Companies Mentioned

  • Philips Respironics
  • GlaxoSmithKline PLC
  • Boehringer Ingelheim GmbH
  • Teva Pharmaceutical Industries Ltd.
  • 3M AptarGroup, Inc.
  • PARI GmbH
  • F. Hoffmann-La Roche AG
  • Gilbert Technologies
  • AstraZeneca PLC

Table Information